Table 2.
Preventive Recombinant Vesicular Stomatitis Virus–Based Ebola and Marburg Virus Vaccines in Nonhuman Primates
| Gene product (species or strain) | Route of vaccine | Vaccine dose, PFU | No. of doses | NHP species | Challenge species | Survivors, n/Total, n | Viremic, n/Total, n | Illness, n/Total, n | Reference |
| GP (Z) | IM | 107 | 1 | Cynomolgus | EBOV-Zairea | 4/4 | 0/4 | 0/4 | [4] |
| GP (Z) | IM | 107 | 1 | Cynomolgus | EBOV-Zairea | 2/2 | 0/2 | 0/2 | [13] |
| GP (Z) | IM | 107 | 1 | Cynomolgus | EBOV-Zaireb | 3/3 | 0/3 | 0/3 | [9] |
| GP (Z) + GP (S) + GP (M-Musoke) | IM | 107 | 1 | Cynomolgus | EBOV-Zairea | 3/3 | 0/3 | 0/3 | [12] |
| GP (Z) + GP (S) + GP (M-Musoke) | IM | 107 | 1 | Cynomolgus | EBOV-Sudana | 2/2 | 0/2 | 0/2 | [12] |
| GP (Z) + GP (S) + GP (M-Musoke) | IM | 107 | 1 | Cynomolgus | EBOV-Ivory Coasta | 3/3 | 0/3 | 0/3 | [12] |
| GP (Z) | IM | 107 | 1 | Cynomolgus | EBOV-Sudana | 0/1 | 1/1 | 1/1 | [12] |
| GP (Z) + GP (S) + GP (M-Musoke) | IM | 107 | 2 | Rhesus | EBOV-Sudana | 3/3 | 0/3 | 0/3 | [12] |
| GP (Z) | oral | 107 | 1 | Cynomolgus | EBOV-Zairea | 4/4 | NR | 0/4 | [13] |
| GP (Z) | IN. | 107 | 1 | Cynomolgus | EBOV-Zairea | 4/4 | NR | 0/4 | [13] |
| GP (M-Musoke) | IM | 107 | 1 | Cynomolgus | MARV-Musokea | 4/4 | 0/4 | 0/4 | [4] |
| GP (M-Musoke) | IM | 107 | 1 | Cynomolgus | MARV-Musokea | 1/1 | 0/1 | 0/1 | [5] |
| GP (M-Musoke) | IM | 107 | 1 | Cynomolgus | MARV-Ravna | 3/3 | 0/3 | 0/3 | [5] |
| GP (M-Musoke) | IM | 107 | 1 | Cynomolgus | MARV-Angolaa | 3/3 | 0/3 | 0/3 | [5] |
| GP (M-Musoke) | IM | 107 | 1 | Cynomolgus | MARV-Musokeb | 4/4 | 0/4 | 0/4 | [9] |
| GP (Z) + GP (S) + GP (M-Musoke) | IM | 107 | 1 | Cynomolgus | MARV-Musokea | 3/3 | 0/3 | 0/3 | [12] |
NOTE. PFU, plaque-forming units; NHP, nonhuman primate; GP, glycoprotein; IM, intramuscular; IN, intranasal; M, Lake Victoria marburgvirus (MARV); NP, nucleoprotein; NR, not reported, S, Sudan ebolavirus; VP, virion protein; Z, Zaire ebolavirus.
a
intramuscular.
b
aerosol.